Rising Pharma Holdings recalled 13,440 bottles of Cetirizine Hydrochloride Tablets on September 12, 2025. The tablets are imprinted with incorrect identification. This recall affects consumers nationwide.
Tablet/Capsules Imprinted with Wrong ID
Consumers and healthcare providers should stop using this product immediately. Contact JB Chemicals and Pharmaceuticals Ltd or your healthcare provider for guidance. Notification method: Letter
The recalled product is Cetirizine Hydrochloride Tablets USP 10 mg, packaged in 500-tablet bottles. Manufactured by Unique Pharmaceuticals Labs in Mumbai, India, it is distributed by Rising Pharma Holdings, Inc. The affected lot numbers are PY925014 and PY925013, with an expiration date of January 31, 2028.
The tablets are imprinted with the wrong identification, which poses a risk of incorrect medication being dispensed. This error can lead to serious health consequences for users.
No injuries or incidents have been reported due to the mislabeling as of the recall date. However, the potential for harm remains high.
Consumers should stop using the product immediately. Contact JB Chemicals and Pharmaceuticals Ltd or your healthcare provider for guidance and possible return instructions.
For more information, consumers can visit the FDA website or contact Rising Pharma Holdings directly.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.